Original Article Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial
暂无分享,去创建一个
Daoud M. Meerzaman | K. Buetow | J. M. Kelley | P. Rosenberg | M. Greene | Ying Hu | R. Clifford | G. Tang | J. Costantino | D. Meerzaman | B. Dunn | N. Kazerouni | Biostatistics Branch | E. Jefferson
[1] J. Leon,et al. The AmpliChip™ CYP450 Genotyping Test , 2012, Molecular Diagnosis & Therapy.
[2] R. Weinshilboum,et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Fasching,et al. CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification , 2010, Clinical Cancer Research.
[4] Hein Putter,et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Yusuke Nakamura,et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Lash,et al. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Goetz,et al. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen , 2010, Cancer.
[8] J. Peppercorn,et al. CYP2D6 testing in breast cancer: ready for prime time? , 2009, Oncology.
[9] D. Berry,et al. Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium. , 2009 .
[10] M. Beckmann,et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.
[11] H. Sørensen,et al. Genotype-guided tamoxifen therapy: time to pause for reflection? , 2009, The Lancet. Oncology.
[12] C. V. D. van de Velde,et al. Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.
[13] Shufeng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.
[14] C. Alonso,et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment , 2009, Breast Cancer Research and Treatment.
[15] F. Couch,et al. Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance , 2008, Clinical Cancer Research.
[16] Lei He,et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] S. Horvath,et al. Variations in DNA elucidate molecular networks that cause disease , 2008, Nature.
[18] Michael Friendly,et al. Causal Modeling and the Origins of Path Analysis , 2007 .
[19] S. Wingren,et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.
[20] L. Kuller,et al. Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women , 2006, Journal of Carcinogenesis.
[21] David A. Flockhart,et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.
[22] G. Heinze,et al. Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer , 2006, Breast Cancer Research and Treatment.
[23] Fergus J Couch,et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Wolff,et al. Associations between ERα, ERβ, and AR Genotypes and Colon and Rectal Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[25] E. Schadt. Exploiting naturally occurring DNA variation and molecular profiling data to dissect disease and drug response traits. , 2005, Current opinion in biotechnology.
[26] Yasushi Saito,et al. Association of cytosine-adenine repeat polymorphism of the estrogen receptor-beta gene with menopausal symptoms. , 2005, Gender medicine.
[27] J. Scheys,et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.
[28] L. Skoog,et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.
[29] Bjarni V. Halldórsson,et al. Estrogen Receptor Genotypes and Haplotypes Associated with Breast Cancer Risk , 2004, Cancer Research.
[30] A. Whittemore,et al. Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study , 2004, Breast Cancer Research.
[31] K. Humphreys,et al. Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study , 2004, Breast Cancer Research.
[32] I. Gut. DNA analysis by MALDI‐TOF mass spectrometry , 2004, Human mutation.
[33] K. Heimdal,et al. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility , 1994, Human Genetics.
[34] R. Baumgartner,et al. Estrogen Receptor β Dinucleotide (CA) Repeat Polymorphism is Significantly Associated with Bone Mineral Density in Postmenopausal Women , 2004, Calcified Tissue International.
[35] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[36] T. Thum,et al. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. , 2002, Clinical chemistry.
[37] R. Zeillinger,et al. Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. , 2002, Gynecologic oncology.
[38] Charles R Cantor,et al. The use of MassARRAY technology for high throughput genotyping. , 2002, Advances in biochemical engineering/biotechnology.
[39] T. Walsh,et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.
[40] J. Tanus-Santos,et al. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. , 2001, Pharmacogenetics.
[41] M Schwab,et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.
[42] P. Donnelly,et al. A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.
[43] J. Cerhan,et al. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[44] D. Eccles,et al. Polymorphic variation in CYP19 and the risk of breast cancer. , 2001, Carcinogenesis.
[45] R. Strausberg,et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[46] G. Coetzee,et al. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. , 2001, Cancer research.
[47] Satoshi Inoue,et al. Association of estrogen receptor β (ESR2) gene polymorphism with blood pressure , 2000, Journal of Human Genetics.
[48] W. Willett,et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. , 2000 .
[49] B. Ponder,et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. , 2000, Carcinogenesis.
[50] Y. Benjamini,et al. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics , 1999 .
[51] S. Coughlin,et al. Genetic polymorphisms and risk of breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[52] M A Province,et al. The Future of Path Analysis, Segregation Analysis, and Combined Models for Genetic Dissection of Complex Traits , 1999, Human Heredity.
[53] W. Willett,et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.
[54] K. Buetow,et al. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.
[55] E. Taioli,et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. , 1999, Cancer detection and prevention.
[56] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[57] A. Børresen-Dale,et al. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.
[58] Hajime Orimo,et al. Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor β locus , 1998, Journal of Human Genetics.
[59] N. Roodi,et al. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. , 1998, Cancer research.
[60] J. Benítez,et al. CYP2D6 genotypes in Spanish women with breast cancer. , 1996, Cancer letters.
[61] Y. Ouchi,et al. Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. , 1995, Biochemical and biophysical research communications.
[62] J. Freudenheim,et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. , 1995, Cancer research.
[63] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[64] L. Pickle,et al. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. , 1993, Pharmacogenetics.
[65] P. Ueland,et al. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. , 1991, Cancer research.
[66] P. Lønning,et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. , 1990, Cancer research.
[67] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[68] S. Lundgren,et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. , 1989, Cancer research.
[69] Ching Chun Li. Path Analysis: A Primer , 1977 .
[70] Robert J. Beaver,et al. Path Analysis: A Primer. , 1976 .
[71] Nathan Mantel,et al. Chi-square tests with one degree of freedom , 1963 .
[72] S. Wright,et al. The Relative Importance of Heredity and Environment in Determining the Piebald Pattern of Guinea-Pigs. , 1920, Proceedings of the National Academy of Sciences of the United States of America.